Literature DB >> 12387695

Review of sertraline in post-traumatic stress disorder.

Ann C Schwartz1, Barbara O Rothbaum.   

Abstract

Sertraline (Zoloft trade mark, Pfizer) is a selective serotonin re-uptake inhibitor (SSRI) with proven efficacy in the treatment of post-traumatic stress disorder (PTSD). PTSD is a serious, complex and often chronic mental illness that may follow exposure to a traumatic event. The high prevalence of traumatic events and PTSD in the general population and the resulting distress and dysfunction present a need for the systematic study of the efficacy and effectiveness of treatments for PTSD. Sertraline offers advantages over the older antidepressants, including demonstrated efficacy in PTSD, improved tolerability and low risk of lethality in overdose. Sertraline's efficacy, favourable tolerability profile and relatively weak effect on the cytochrome P450 system are factors that contribute to make it a first-line agent of choice in the treatment of PTSD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12387695     DOI: 10.1517/14656566.3.10.1489

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  1 in total

1.  Failed efficacy of ziprasidone in the treatment of post-traumatic stress disorder.

Authors:  Sriram Ramaswamy; David Driscoll; Lynette M Smith; Subhash C Bhatia; Frederick Petty
Journal:  Contemp Clin Trials Commun       Date:  2015-12-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.